Carlumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | MCP-1 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number |
915404-94-3  |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6442H9966N1706O2018S40 |
| Molar mass | 144.88 kg/mol |
 (what is this?) (verify) | |
Carlumab is a human monoclonal antibody designed for oncology and immune indications.[1][2]
Carlumab was developed by Johnson & Johnson.
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Carlumab" (PDF). American Medical Association.
- ↑ World Health Organization (2010). "Proposed International Nonproprietary Names: List 104" (PDF). WHO Drug Information. 24 (4). Geneva: World Health Organization. p. 361. ISSN 1010-9609. Retrieved 17 August 2015.
This article is issued from Wikipedia - version of the 9/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.